Showing 101-110 of 7591 results for "".
Wet Wipe Applicators: Exploring the Future of Topical Drug Delivery
https://practicaldermatology.com/topics/psoriasis/wet-wipe-applicators-exploring-the-future-of-topical-drug-delivery/23448/The answer to convenience and adherence could be a wipe.Colloidal Oatmeal in the Treatment of Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/colloidal-oatmeal-in-the-treatment-of-atopic-dermatitis/23338/Is this plant-based intervention an effective treatment alternative?The Shape of Atopic Dermatitis
https://practicaldermatology.com/columns/clinical-focus-1/the-shape-of-atopic-dermatitis/23037/What do we really mean when we talk about flares or waxing and waning presentations?Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsTazarotene Lotion for Acne
https://practicaldermatology.com/topics/acne-rosacea/tazarotene-lotion-for-acne/23388/Tazarotene Lotion 0.045% offers dermatologists a new option that is effective and well tolerated for treating acne.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeHilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Can AI and Digital Innovation Improve the Patient Experience?
https://practicaldermatology.com/topics/practice-management/can-ai-and-digital-innovation-improve-the-patient-experience/23964/Embrace AI and how it can help improve points of contact with your patients.